Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tozinameran - BioNTech/Pfizer

Next Previous
Drug Profile

Tozinameran - BioNTech/Pfizer

Alternative Names: BNT 162; BNT 162b2; Bnt-162b2; BNT162b2 vaccine; BNT162b2SA; COMIRNATY; COMIRNATY JN.1; COMIRNATY LP.8.1; COVID-19 Vaccine, mRNA - BioNTech/Pfizer; LP.8.1-adapted monovalent COVID-19 vaccine; Omi LP.8.1; Omicron JN.1-adapted monovalent vaccine - BioNTech/Pfizer; Omicron KP.2-adapted monovalent vaccine - BioNTech/Pfizer; PF-07302048; Pfizer-BioNTech COVID-19 vaccine; Pfizer-BioNTech vaccine; SARS-CoV-2 RNA vaccine - BioNTech/Pfizer

Latest Information Update: 12 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech; University of Roma La Sapienza
  • Developer BioNTech; Pfizer; Pfizer Japan; Shanghai Fosun Pharmaceutical
  • Class COVID-19 vaccines; RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed COVID 2019 infections
  • Phase II SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 12 Feb 2026 Fred Hutchinson Cancer Center and Arcturus Therapeutics plans a phase II trial for COVID 2019 infections in USA (IM) in September 2026 (NCT07390968)
  • 10 Dec 2025 BioNTech initiates a phase III trial in COVID-2019 infections (Prevention, In adults) in USA (IM) (NCT07300839)
  • 30 Oct 2025 BioNTech initiates the phase III trial for COVID-2019 infections in USA (NCT07222384)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top